Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis
Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Li, Baofeng [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Association of Surgeons of India 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Surgery - Springer-Verlag, 2007, 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 |
|---|---|
| Übergeordnetes Werk: |
volume:85 ; year:2022 ; number:Suppl 2 ; day:15 ; month:04 ; pages:584-596 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12262-022-03389-1 |
|---|
| Katalog-ID: |
SPR053940830 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053940830 | ||
| 003 | DE-627 | ||
| 005 | 20231202064640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231202s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12262-022-03389-1 |2 doi | |
| 035 | |a (DE-627)SPR053940830 | ||
| 035 | |a (SPR)s12262-022-03389-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Baofeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Association of Surgeons of India 2022 | ||
| 520 | |a Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. | ||
| 650 | 4 | |a Neoadjuvant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemoimmunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Surgical resection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-small lung cancer, Meta-analysis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Zhang, Guangxin |4 aut | |
| 700 | 1 | |a Jin, Chengyan |4 aut | |
| 700 | 1 | |a Zhao, Yinghao |4 aut | |
| 700 | 1 | |a Hua, Peiyan |4 aut | |
| 700 | 1 | |a Tong, Ti |0 (orcid)0000-0001-8686-6080 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Surgery |d Springer-Verlag, 2007 |g 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 |w (DE-627)SPR024596493 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2022 |g number:Suppl 2 |g day:15 |g month:04 |g pages:584-596 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12262-022-03389-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2022 |e Suppl 2 |b 15 |c 04 |h 584-596 | ||
| author_variant |
b l bl g z gz c j cj y z yz p h ph t t tt |
|---|---|
| matchkey_str |
libaofengzhangguangxinjinchengyanzhaoyin:2022----:fetvnsadaeyfeajvnimnteayobndihhmteayneetbeo |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1007/s12262-022-03389-1 doi (DE-627)SPR053940830 (SPR)s12262-022-03389-1-e DE-627 ger DE-627 rakwb eng Li, Baofeng verfasserin aut Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Surgeons of India 2022 Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 Zhang, Guangxin aut Jin, Chengyan aut Zhao, Yinghao aut Hua, Peiyan aut Tong, Ti (orcid)0000-0001-8686-6080 aut Enthalten in Indian Journal of Surgery Springer-Verlag, 2007 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 (DE-627)SPR024596493 nnns volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 https://dx.doi.org/10.1007/s12262-022-03389-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 85 2022 Suppl 2 15 04 584-596 |
| spelling |
10.1007/s12262-022-03389-1 doi (DE-627)SPR053940830 (SPR)s12262-022-03389-1-e DE-627 ger DE-627 rakwb eng Li, Baofeng verfasserin aut Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Surgeons of India 2022 Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 Zhang, Guangxin aut Jin, Chengyan aut Zhao, Yinghao aut Hua, Peiyan aut Tong, Ti (orcid)0000-0001-8686-6080 aut Enthalten in Indian Journal of Surgery Springer-Verlag, 2007 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 (DE-627)SPR024596493 nnns volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 https://dx.doi.org/10.1007/s12262-022-03389-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 85 2022 Suppl 2 15 04 584-596 |
| allfields_unstemmed |
10.1007/s12262-022-03389-1 doi (DE-627)SPR053940830 (SPR)s12262-022-03389-1-e DE-627 ger DE-627 rakwb eng Li, Baofeng verfasserin aut Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Surgeons of India 2022 Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 Zhang, Guangxin aut Jin, Chengyan aut Zhao, Yinghao aut Hua, Peiyan aut Tong, Ti (orcid)0000-0001-8686-6080 aut Enthalten in Indian Journal of Surgery Springer-Verlag, 2007 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 (DE-627)SPR024596493 nnns volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 https://dx.doi.org/10.1007/s12262-022-03389-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 85 2022 Suppl 2 15 04 584-596 |
| allfieldsGer |
10.1007/s12262-022-03389-1 doi (DE-627)SPR053940830 (SPR)s12262-022-03389-1-e DE-627 ger DE-627 rakwb eng Li, Baofeng verfasserin aut Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Surgeons of India 2022 Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 Zhang, Guangxin aut Jin, Chengyan aut Zhao, Yinghao aut Hua, Peiyan aut Tong, Ti (orcid)0000-0001-8686-6080 aut Enthalten in Indian Journal of Surgery Springer-Verlag, 2007 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 (DE-627)SPR024596493 nnns volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 https://dx.doi.org/10.1007/s12262-022-03389-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 85 2022 Suppl 2 15 04 584-596 |
| allfieldsSound |
10.1007/s12262-022-03389-1 doi (DE-627)SPR053940830 (SPR)s12262-022-03389-1-e DE-627 ger DE-627 rakwb eng Li, Baofeng verfasserin aut Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Surgeons of India 2022 Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 Zhang, Guangxin aut Jin, Chengyan aut Zhao, Yinghao aut Hua, Peiyan aut Tong, Ti (orcid)0000-0001-8686-6080 aut Enthalten in Indian Journal of Surgery Springer-Verlag, 2007 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 (DE-627)SPR024596493 nnns volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 https://dx.doi.org/10.1007/s12262-022-03389-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 85 2022 Suppl 2 15 04 584-596 |
| language |
English |
| source |
Enthalten in Indian Journal of Surgery 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 |
| sourceStr |
Enthalten in Indian Journal of Surgery 85(2022), Suppl 2 vom: 15. Apr., Seite 584-596 volume:85 year:2022 number:Suppl 2 day:15 month:04 pages:584-596 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Neoadjuvant Chemoimmunotherapy Surgical resection Non-small lung cancer, Meta-analysis |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Surgery |
| authorswithroles_txt_mv |
Li, Baofeng @@aut@@ Zhang, Guangxin @@aut@@ Jin, Chengyan @@aut@@ Zhao, Yinghao @@aut@@ Hua, Peiyan @@aut@@ Tong, Ti @@aut@@ |
| publishDateDaySort_date |
2022-04-15T00:00:00Z |
| hierarchy_top_id |
SPR024596493 |
| id |
SPR053940830 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR053940830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231202064640.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231202s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12262-022-03389-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR053940830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12262-022-03389-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Baofeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Association of Surgeons of India 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemoimmunotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Surgical resection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-small lung cancer, Meta-analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Guangxin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jin, Chengyan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Yinghao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Peiyan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tong, Ti</subfield><subfield code="0">(orcid)0000-0001-8686-6080</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 2007</subfield><subfield code="g">85(2022), Suppl 2 vom: 15. Apr., Seite 584-596</subfield><subfield code="w">(DE-627)SPR024596493</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:85</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:584-596</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12262-022-03389-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">85</subfield><subfield code="j">2022</subfield><subfield code="e">Suppl 2</subfield><subfield code="b">15</subfield><subfield code="c">04</subfield><subfield code="h">584-596</subfield></datafield></record></collection>
|
| author |
Li, Baofeng |
| spellingShingle |
Li, Baofeng misc Neoadjuvant misc Chemoimmunotherapy misc Surgical resection misc Non-small lung cancer, Meta-analysis Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| authorStr |
Li, Baofeng |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR024596493 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis Neoadjuvant (dpeaa)DE-He213 Chemoimmunotherapy (dpeaa)DE-He213 Surgical resection (dpeaa)DE-He213 Non-small lung cancer, Meta-analysis (dpeaa)DE-He213 |
| topic |
misc Neoadjuvant misc Chemoimmunotherapy misc Surgical resection misc Non-small lung cancer, Meta-analysis |
| topic_unstemmed |
misc Neoadjuvant misc Chemoimmunotherapy misc Surgical resection misc Non-small lung cancer, Meta-analysis |
| topic_browse |
misc Neoadjuvant misc Chemoimmunotherapy misc Surgical resection misc Non-small lung cancer, Meta-analysis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Surgery |
| hierarchy_parent_id |
SPR024596493 |
| hierarchy_top_title |
Indian Journal of Surgery |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR024596493 |
| title |
Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| ctrlnum |
(DE-627)SPR053940830 (SPR)s12262-022-03389-1-e |
| title_full |
Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| author_sort |
Li, Baofeng |
| journal |
Indian Journal of Surgery |
| journalStr |
Indian Journal of Surgery |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
584 |
| author_browse |
Li, Baofeng Zhang, Guangxin Jin, Chengyan Zhao, Yinghao Hua, Peiyan Tong, Ti |
| container_volume |
85 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Li, Baofeng |
| doi_str_mv |
10.1007/s12262-022-03389-1 |
| normlink |
(ORCID)0000-0001-8686-6080 |
| normlink_prefix_str_mv |
(orcid)0000-0001-8686-6080 |
| title_sort |
effectiveness and safety of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer: a meta-analysis |
| title_auth |
Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| abstract |
Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. © Association of Surgeons of India 2022 |
| abstractGer |
Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. © Association of Surgeons of India 2022 |
| abstract_unstemmed |
Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC. © Association of Surgeons of India 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
Suppl 2 |
| title_short |
Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis |
| url |
https://dx.doi.org/10.1007/s12262-022-03389-1 |
| remote_bool |
true |
| author2 |
Zhang, Guangxin Jin, Chengyan Zhao, Yinghao Hua, Peiyan Tong, Ti |
| author2Str |
Zhang, Guangxin Jin, Chengyan Zhao, Yinghao Hua, Peiyan Tong, Ti |
| ppnlink |
SPR024596493 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12262-022-03389-1 |
| up_date |
2024-07-03T23:02:51.015Z |
| _version_ |
1803600811540873217 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR053940830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231202064640.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231202s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12262-022-03389-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR053940830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12262-022-03389-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Baofeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Association of Surgeons of India 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract With the immunotherapy widely used in lung cancer, neoadjuvant immunotherapy has also been used in the resectable non-small cell lung cancer (NSCLC). However, the result of neoadjuvant immunotherapy was unsatisfied, and the improvement of prognosis in NSCLC was limited. In this essay, we tried to explore the effectiveness and safety of neoadjuvant chemoimmunotherapy, a new treatment schedule for NSCLC. This meta-analysis was enrolled in International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42021249716. This meta-analysis assembled ten relevant articles in online databases reported before May 12, 2021, including PubMed, Embase, and Cochrane Library. Aiming to evaluate the effectiveness and safety of neoadjuvant chemoimmunotherapy, the perspective of odds ratio (OR), 95% confidence interval (CI), heterogeneity and subgroup analysis was calculated and reported in this meta-analysis. There were 293 patients in ten studies. The effectiveness of neoadjuvant chemoimmunotherapy was evaluated by major pathological response (MPR) and pathological complete response (pCR). The pooled odds ratio (OR) of MPR and pCR was 1.56 (95% CI, 1.15–2.11, P = 0.004) and 0.34 (95%CI, 0.21–0.56, P < 0.0001), which was significantly higher than neoadjuvant immunotherapy (MPR: OR = 0.59; 95%CI, 0.36–0.98, P = 0.04; pCR: OR = 0.16; 95% CI, 0.09–0.27, P < 0.00001). The incidence of surgical resection in neoadjuvant chemoimmunotherapy was 83.6%. The percentage of Grade ≥ 3 treatment-related adverse events (TRAEs) was 33.3%, giving unsatisfied results compared to 12.5% in the meta-analysis of neoadjuvant immunotherapy. Our results revealed the effectiveness and safety of neoadjuvant chemoimmunotherapy in locally advanced resectable NSCLC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemoimmunotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Surgical resection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-small lung cancer, Meta-analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Guangxin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jin, Chengyan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Yinghao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Peiyan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tong, Ti</subfield><subfield code="0">(orcid)0000-0001-8686-6080</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 2007</subfield><subfield code="g">85(2022), Suppl 2 vom: 15. Apr., Seite 584-596</subfield><subfield code="w">(DE-627)SPR024596493</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:85</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:584-596</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12262-022-03389-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">85</subfield><subfield code="j">2022</subfield><subfield code="e">Suppl 2</subfield><subfield code="b">15</subfield><subfield code="c">04</subfield><subfield code="h">584-596</subfield></datafield></record></collection>
|
| score |
7.4008837 |